The coronavirus disease 2019 (COVID-19) pandemic is having an enormous impact on the healthcare system worldwide directly and indirectly. To mitigate the increasing number of patients with COVID-19, the World Health Organization recommends applying reactive measures to the general public such as stopping all nonessential services, practicing social distancing, and confining individuals to their homes with the goal of reducing person-to-person contact and, therefore, decreasing viral spread.^[@R1]^ Stroke due to large vessel occlusion is a neurological emergency and is, fortunately, most oftentimes detected during person-to-person interactions.^[@R2]^ These interactions facilitate rapid assessment and diagnosis allowing patients to meet the criteria for endovascular therapy (EVT), the standard of care for large vessel occlusion-related patients with stroke.^[@R3]^ The American Stroke Association, European Stroke Organization, and European Society of Minimally Invasive Neurological Therapy recommend prompt EVT during the current pandemic because of the high mortality rate and severe neurological disability in untreated patients.^[@R4],[@R5]^ Unfortunately, reports suggest a decrease in the number of EVTs during the pandemic, reportedly a 25.3% decrease in China and a 21% decrease in France compared the number of EVTs performed before the COVID-19 pandemic, which may be explained by patients' ineligibility for EVT due to increased delays from stroke onset to treatment.^[@R6],[@R7]^

We sought to determine whether there has been a significant decrease in number of EVTs performed for stroke treatment, in addition to a possible increase in stroke onset-to-groin puncture time. The study design, raw data, statistical analysis, and any related materials are available by request to the first author (Dr Hajdu). The institutional review board at each participating site approved analysis and publication of anonymized and retrospectively obtained data. Informed consent was not required.

We analyzed consecutive EVT procedures performed in 17 stroke centers from November 11, 2019, to April 15, 2020. Among the participating centers, 6 were based in France, 3 in Portugal, 2 in Italy, 2 in Switzerland, 1 in Spain, 1 in Germany, 1 in Canada, and 1 in the United States with an annual mean EVT case load of 187 (\[95% CI, 159--215\]; min: 96; max: 334).

Among the centers included in this study, 1600 EVT procedures were available for analysis of which 776 had data on stroke onset-to-groin puncture time. Despite the limitation of the latter being available in approximately half of our cohort, we possessed a sufficiently large amount of observations for a robust onset-to-groin puncture time analysis. Official confinement dates were identified for each country varying from March 9, 2020, in Italy to March 23, 2020, in Ontario, Canada. Then based on these dates, 2 periods were established accordingly as before COVID-19 confinement when social life and medical operations were functioning normally and after COVID-19 confinement when government restrictions, social distancing, and confinement were applied.

We calculated (1) mean number of EVTs performed and (2) mean stroke onset-to-groin puncture time interval (minutes) per hospital and per 2-week interval.

For descriptive purpose, we reported mean number of EVTs performed per hospital per 2-week interval, which ranged between 6.4 and 10.4 with a 4-week moving average that globally declined with time (Figure \[A\]). We then compared distributions (non-normal) between the 2 groups (before COVID-19 confinement versus after COVID-19 confinement) using 2-sample Wilcoxon rank-sum tests.

![**Endovascular therapy (EVT) for stroke before and after coronavirus disease 2019 (COVID-19) confinement measures.**\
**A**, Visual representation of mean number of EVT cases for stroke per hospital per 2-wk period and number of confirmed COVID-19 cases in Switzerland, France, Italy, Germany, Spain, Portugal, Canada, and the United States from November 1, 2019 to April 15, 2020. **B**, Mean number of EVTs for stroke per hospital per 2-wk period and (C) mean stroke onset-to-groin puncture time before and after COVID-19 confinement.](str-publish-ahead-of-print-10.1161.strokeaha.120.030794-g001){#F1}

The results showed a significant decrease in mean number of EVTs performed per hospital per 2-week interval between before COVID-19 confinement (9.0 \[95% CI, 7.8--10.1\]) and after COVID-19 confinement (6.1 \[95% CI, 4.5--7.7\]), (*P*\<0.001; Figure \[B\]). Additionally, we observed a significant increase in mean stroke onset-to-groin puncture time (*P*\<0.001), between before COVID-19 confinement (300.3 minutes \[95% CI, 285.3--315.4\]) and after COVID-19 confinement (354.5 minutes \[95% CI, 316.2--392.7\]; Figure \[C\]).

Interestingly, many physicians involved in stroke management would have predicted an increase in the number of acute ischemic strokes and thus EVT due to the known risk of viral-induced hypercoagulable states and reports on cardiovascular complications related to COVID-19.^[@R8]^ Critically ill patients with COVID-19 have been reported to suffer from a remarkably high rate of thrombotic disease.^[@R9],[@R10]^ Paradoxically, our analysis shows an estimated 32% reduction in EVT procedures and an estimated 54-minute increase in symptom onset-to-groin puncture time after confinement measures were put into place. This is similar to the data regarding the reduction of emergency cardiac catheterizations in the United States, Spain, and Italy.^[@R11]--[@R13]^ While a more comprehensive report using data from additional stroke centers with corresponding regional analyses is warranted, we hypothesize that decreased person-to-person contact due to social distancing has led to a decrease in stroke admission and thus a drop in EVT, while delayed stroke recognition has led to an increase in prehospital delay time. These effects would lead to an increase in stroke-related morbidity and mortality and, therefore, an unfortunate indirect consequence of the reactive measures promoted by health organizations during the pandemic. While more studies are required to confirm our findings, national health organizations and the World Health Organization should be alerted to this trend and COVID-19 related recommendations in the meantime should consider integrating strategies for medical emergencies such as stroke to avoid irreversible delays in acute stroke management.
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